GFPT1
Basic information
Region (hg38): 2:69319780-69387250
Previous symbols: [ "GFPT" ]
Links
Phenotypes
GenCC
Source:
- congenital myasthenic syndrome 12 (Strong), mode of inheritance: AR
- congenital myasthenic syndrome 12 (Strong), mode of inheritance: AR
- congenital myasthenic syndrome 12 (Moderate), mode of inheritance: AR
- congenital myasthenic syndromes with glycosylation defect (Supportive), mode of inheritance: AR
- congenital myasthenic syndrome 12 (Definitive), mode of inheritance: AR
- congenital myasthenic syndrome 12 (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Myasthenic syndrome, congenital 12 | AR | Musculoskeletal; Pharmacogenomic | Acetylcholinesterase inhibitors have been shown to result in a favorable treatment response; Avoidance of certain agents involved in neuromuscular transmission is indicated (eg, ciprofloxacin, chloroquine, lithium, phenytoin, beta-blockers, procainamide); Additional neurologic monitoring in pregnancy may be beneficial | Musculoskeletal; Neurologic | 8664562; 12467753; 21310273; 23108489 |
ClinVar
This is a list of variants' phenotypes submitted to
- Congenital myasthenic syndrome 12 (17 variants)
- not provided (3 variants)
- Congenital myasthenic syndrome (1 variants)
- GFPT1-related disorder (1 variants)
- Abnormality of the musculature (1 variants)
- GFPT1-related myasthenic syndrome (1 variants)
- Congenital myasthenic syndrome 12;Congenital myasthenic syndrome 4C (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the GFPT1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 66 | 71 | ||||
missense | 120 | 125 | ||||
nonsense | 8 | |||||
start loss | 0 | |||||
frameshift | 10 | |||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 5 | |||||
splice region | 1 | 9 | 18 | 2 | 30 | |
non coding | 113 | 96 | 60 | 269 | ||
Total | 17 | 10 | 238 | 162 | 63 |
Highest pathogenic variant AF is 0.0000197
Variants in GFPT1
This is a list of pathogenic ClinVar variants found in the GFPT1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-69319811-C-T | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 13, 2018) | ||
2-69319823-A-G | Congenital myasthenic syndrome 12 | Benign (Jan 13, 2018) | ||
2-69319905-C-T | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 12, 2018) | ||
2-69320053-G-A | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 13, 2018) | ||
2-69320063-T-C | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 12, 2018) | ||
2-69320087-A-C | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 13, 2018) | ||
2-69320095-G-A | Congenital myasthenic syndrome 12 | Benign (Jan 12, 2018) | ||
2-69320104-G-C | Congenital myasthenic syndrome 12 | Benign (Jan 13, 2018) | ||
2-69320150-C-A | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 12, 2018) | ||
2-69320173-G-A | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 13, 2018) | ||
2-69320186-C-A | Congenital myasthenic syndrome 12 | Likely benign (Jan 13, 2018) | ||
2-69320287-AC-A | Congenital Myasthenic Syndrome, Recessive | Uncertain significance (Jun 14, 2016) | ||
2-69320305-T-C | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 13, 2018) | ||
2-69320369-G-A | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 12, 2018) | ||
2-69320389-C-T | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 12, 2018) | ||
2-69320425-T-C | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 13, 2018) | ||
2-69320476-A-G | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 13, 2018) | ||
2-69320516-G-A | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 12, 2018) | ||
2-69320675-C-A | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 13, 2018) | ||
2-69320713-G-A | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 13, 2018) | ||
2-69320725-T-C | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 13, 2018) | ||
2-69320741-T-C | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 13, 2018) | ||
2-69320752-C-T | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 13, 2018) | ||
2-69320757-C-T | Congenital myasthenic syndrome 12 | Uncertain significance (Jan 13, 2018) | ||
2-69320787-C-CA | Congenital Myasthenic Syndrome, Recessive | Uncertain significance (Jun 14, 2016) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
GFPT1 | protein_coding | protein_coding | ENST00000357308 | 20 | 67478 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.900 | 0.100 | 125730 | 0 | 18 | 125748 | 0.0000716 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 4.35 | 151 | 394 | 0.383 | 0.0000220 | 4617 |
Missense in Polyphen | 30 | 155.75 | 0.19262 | 1850 | ||
Synonymous | 1.04 | 112 | 127 | 0.883 | 0.00000641 | 1300 |
Loss of Function | 4.92 | 8 | 42.7 | 0.187 | 0.00000250 | 488 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000183 | 0.000183 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.000139 | 0.000139 |
European (Non-Finnish) | 0.0000627 | 0.0000615 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000653 | 0.0000653 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Controls the flux of glucose into the hexosamine pathway. Most likely involved in regulating the availability of precursors for N- and O-linked glycosylation of proteins. Regulates the circadian expression of clock genes ARNTL/BMAL1 and CRY1.;
- Pathway
- Alanine, aspartate and glutamate metabolism - Homo sapiens (human);Insulin resistance - Homo sapiens (human);Amino sugar and nucleotide sugar metabolism - Homo sapiens (human);Sialuria or French Type Sialuria;Sialuria or French Type Sialuria;2-Hydroxyglutric Aciduria (D And L Form);Amino Sugar Metabolism;G(M2)-Gangliosidosis: Variant B, Tay-sachs disease;Tay-Sachs Disease;Homocarnosinosis;Hyperinsulinism-Hyperammonemia Syndrome;Succinic semialdehyde dehydrogenase deficiency;4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency;Salla Disease/Infantile Sialic Acid Storage Disease;Glutamate Metabolism;miR-targeted genes in epithelium - TarBase;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;miR-targeted genes in squamous cell - TarBase;XBP1(S) activates chaperone genes;Aminosugars metabolism;Fructose Mannose metabolism;Post-translational protein modification;Metabolism of proteins;UDP-<i>N</i>-acetyl-D-glucosamine biosynthesis II;Synthesis of UDP-N-acetyl-glucosamine;Synthesis of substrates in N-glycan biosythesis;Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein;Asparagine N-linked glycosylation
(Consensus)
Recessive Scores
- pRec
- 0.509
Intolerance Scores
- loftool
- 0.332
- rvis_EVS
- -0.49
- rvis_percentile_EVS
- 22.09
Haploinsufficiency Scores
- pHI
- 0.701
- hipred
- Y
- hipred_score
- 0.663
- ghis
- 0.638
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- K
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.985
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Gfpt1
- Phenotype
- skeleton phenotype; immune system phenotype; limbs/digits/tail phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Zebrafish Information Network
- Gene name
- gfpt1
- Affected structure
- slow muscle cell
- Phenotype tag
- abnormal
- Phenotype quality
- morphology
Gene ontology
- Biological process
- fructose 6-phosphate metabolic process;UDP-N-acetylglucosamine metabolic process;UDP-N-acetylglucosamine biosynthetic process;energy reserve metabolic process;protein N-linked glycosylation;glutamine metabolic process;circadian regulation of gene expression;IRE1-mediated unfolded protein response
- Cellular component
- cytosol;extracellular exosome
- Molecular function
- glutamine-fructose-6-phosphate transaminase (isomerizing) activity;carbohydrate derivative binding